Pro Medicus signs A$25m US contract: What it means for investors

The Pro Medicus Ltd (ASX: PME) share price is on watch today after the company announced a new 7-year, A$25 million contract with Valley Health in the United States, covering its full suite of cloud-based medical imaging solutions.

What did Pro Medicus report?

• Signed a 7-year, A$25 million contract with Valley Health in the U.S.
• Valley Health will implement Visage 7 Viewer, Workflow, Open Archive and Cardiology Imaging
• Contract to be delivered using a cloud-based, transaction-based pricing model
• Migrating Valley Health’s legacy PACS archive to Visage 7 Open Archive
• Go-live implementation target set for Q1 of calendar year 2027

What else do investors need to know?

The Valley Health contract continues Pro Medicus’ momentum in the North American market, expanding its reach in the Mid-Atlantic region. This deal showcases the company’s growing reputation for delivering unified, cloud-based imaging solutions.

Importantly, Valley Health chose to adopt the full range of Visage 7 products, including the cardiology module—reflecting ongoing industry trends toward platform consolidation and cloud adoption. With its flexible, transaction-based pricing, Pro Medicus may also see further upside as usage grows.

What did Pro Medicus management say?

Pro Medicus CEO, Dr Sam Hupert, commented:

Valley Health provides award-winning care to their patients and is committed to improving the health of their region. They join our established customers in Virginia and the Mid-Atlantic, reflecting an ever-growing list of Visage 7 clients opting for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

What’s next for Pro Medicus?

Planning for the Valley Health rollout will commence immediately, with go-live aimed for the first quarter of 2027. The company expects continued growth from its ‘Full Stack +1’ offering, catering to health enterprises looking to modernise and unify their imaging systems.

With a strong pipeline across all segments and growing demand in North America, Pro Medicus appears well placed to build on its position as a leading provider of cloud-based medical imaging software.

Pro Medicus share price snapshot

Over the past 12 months, the Pro Medicus share price has underperformed the S&P/ASX 200 index (ASX: XJO) with a disappointing decline of around 33%.

View Original Announcement

The post Pro Medicus signs A$25m US contract: What it means for investors appeared first on The Motley Fool Australia.

More reading

• Investing in AI stocks on the ASX? Here’s what you should buy
• My top 5 ASX 200 shares to buy and hold
• Why I’d buy CSL, Cochlear, and Pro Medicus shares
• This ASX dividend share just blew me away
• Healthcare results wrap: Are Cogstate and Pro Medicus shares a buy, hold or sell?

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.